Related Experiment Video
Updated: Jul 27, 2025
Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
Published on: February 9, 2019
Lipid Nanoparticles-Based Therapy in Liver Metastasis Management: From Tumor Cell-Directed Strategy to Liver
Yuhan Wang1, Zhenyu Yin1, Lei Gao1
1Lanzhou University Second Hospital, Lanzhou, 730030, People's Republic of China.
Abstract:
Metastasis to the liver, as one of the most frequent metastatic patterns, was associated with poor prognosis. Major drawbacks of conventional therapies in liver metastasis were the lack of metastatic-targeting ability, predominant systemic toxicities and incapability of tumor microenvironment modulations. Lipid nanoparticles-based strategies like galactosylated, lyso-thermosensitive or active-targeting chemotherapeutics liposomes have been explored in liver metastasis management. This review aimed to summarize the state-of-art lipid nanoparticles-based therapies in liver metastasis management. Clinical and translational studies on the lipid nanoparticles in treating liver metastasis were searched up to April, 2023 from online databases. This review focused not only on the updates in drug-encapsulated lipid nanoparticles directly targeting metastatic cancer cells in treating liver metastasis, but more importantly on research frontiers in drug-loading lipid nanoparticles targeting nonparenchymal liver tumor microenvironment components in treating liver metastasis, which showed promise for future clinical oncological practice.
Insights
Lipid nanoparticles offer advanced liver metastasis treatment by targeting cancer cells and the tumor microenvironment. This review highlights their potential to overcome conventional therapy limitations for improved patient outcomes.
Area of Science:
- Oncology
- Nanomedicine
- Drug Delivery
Background:
- Liver metastasis is a frequent metastatic pattern associated with poor prognosis.
- Conventional therapies for liver metastasis suffer from lack of targeting, systemic toxicity, and inability to modulate the tumor microenvironment.
- Lipid nanoparticles (LNPs) present a promising alternative for liver metastasis management.
Purpose of the Study:
- To review the current state-of-the-art LNP-based therapies for liver metastasis.
- To focus on LNPs targeting both metastatic cancer cells and the liver tumor microenvironment.
- To identify promising research frontiers for clinical application.
Main Methods:
- Comprehensive literature search of clinical and translational studies up to April 2023.
- Focus on LNP strategies including galactosylated, lyso-thermosensitive, and active-targeting liposomes.
- Analysis of studies targeting cancer cells and non-parenchymal liver tumor microenvironment components.
Main Results:
- LNPs demonstrate potential in overcoming limitations of conventional therapies for liver metastasis.
- Drug-encapsulated LNPs show efficacy in directly targeting metastatic cancer cells.
- Emerging research focuses on LNPs targeting the tumor microenvironment for enhanced therapeutic effects.
Conclusions:
- Lipid nanoparticles represent a significant advancement in liver metastasis treatment.
- Targeting the tumor microenvironment with LNPs shows considerable promise for future clinical practice.
- Further research and clinical translation of LNP-based strategies are warranted.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:17The Tumor Microenvironment